- Home
- KLRS vs NMRA Comparison
KLRS vs NMRA Comparison
Compare KLRS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- NMRA
- Stock Information
- Founded
- KLRS 2019
- NMRA 2019
- Country
- KLRS United States
- NMRA United States
- Employees
- KLRS N/A
- NMRA N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- NMRA
- Sector
- KLRS Health Care
- NMRA
- Exchange
- KLRS Nasdaq
- NMRA Nasdaq
- Market Cap
- KLRS 129.0M
- NMRA 121.0M
- IPO Year
- KLRS N/A
- NMRA 2023
- Fundamental
- Price
- KLRS $2.40
- NMRA $0.77
- Analyst Decision
- KLRS Buy
- NMRA Buy
- Analyst Count
- KLRS 1
- NMRA 8
- Target Price
- KLRS N/A
- NMRA $9.29
- AVG Volume (30 Days)
- KLRS 47.1K
- NMRA 847.9K
- Earning Date
- KLRS 08-15-2025
- NMRA 08-05-2025
- Dividend Yield
- KLRS N/A
- NMRA N/A
- EPS Growth
- KLRS N/A
- NMRA N/A
- EPS
- KLRS N/A
- NMRA N/A
- Revenue
- KLRS N/A
- NMRA N/A
- Revenue This Year
- KLRS N/A
- NMRA N/A
- Revenue Next Year
- KLRS N/A
- NMRA N/A
- P/E Ratio
- KLRS N/A
- NMRA N/A
- Revenue Growth
- KLRS N/A
- NMRA N/A
- 52 Week Low
- KLRS $2.32
- NMRA $0.61
- 52 Week High
- KLRS $24.15
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- NMRA 45.74
- Support Level
- KLRS N/A
- NMRA $0.81
- Resistance Level
- KLRS N/A
- NMRA $1.34
- Average True Range (ATR)
- KLRS 0.00
- NMRA 0.10
- MACD
- KLRS 0.00
- NMRA -0.01
- Stochastic Oscillator
- KLRS 0.00
- NMRA 12.55
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.